Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 39.35 USD -2.07% Market Closed
Market Cap: 7.3B USD
Have any thoughts about
Legend Biotech Corp?
Write Note

Wall Street
Price Targets

LEGN Price Targets Summary
Legend Biotech Corp

Wall Street analysts forecast LEGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LEGN is 84.8 USD with a low forecast of 60.6 USD and a high forecast of 99.75 USD.

Lowest
Price Target
60.6 USD
54% Upside
Average
Price Target
84.8 USD
115% Upside
Highest
Price Target
99.75 USD
153% Upside

LEGN Last Price Targets
Legend Biotech Corp

The latest public price target was made on Nov 13, 2024 by Rick Bienkowski from Cantor Fitzgerald , who expects LEGN stock to rise by 111% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Rick Bienkowski
Cantor Fitzgerald
83 USD
Upside 111%
1 day ago
Nov 13, 2024
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
StreetInsider
Gena Wang
Barclays
94 USD
Upside 139%
4 weeks ago
Oct 15, 2024
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
Justin Zelin
BTIG
91 USD
Upside 131%
4 weeks ago
Oct 15, 2024
BTIG Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
StreetInsider
Gena Wang
Johnson Rice
94 USD
Upside 139%
4 weeks ago
Oct 15, 2024
Legend Biotech weakness a buying opportunity, says Barclays
TheFly
Qize Ding
Redburn Partners
86 USD
Upside 119%
1 month ago
Oct 8, 2024
Legend Biotech initiated with a Buy at Redburn Atlantic
TheFly
Edward Tenthoff
Piper Sandler
90 USD
Upside 129%
4 months ago
Jun 17, 2024
Piper Sandler Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
StreetInsider
Asthika Goonewardene
Truist Financial
88 USD
Upside 124%
4 months ago
Jun 17, 2024
Legend Biotech initiated with a Buy at Truist
TheFly
James Shin
Deutsche Bank
60 USD
Upside 52%
5 months ago
May 23, 2024
Deutsche Bank Starts Legend Biotech Corp. (LEGN) at Buy
StreetInsider
Matthew Harrison
Morgan Stanley
82 USD
Upside 108%
5 months ago
May 17, 2024
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan Stanley
StreetInsider
Leonid Timashev
RBC Capital
86 USD
Upside 119%
6 months ago
May 14, 2024
Legend Biotech price target raised to $86 from $85 at RBC Capital
TheFly
George Farmer
Scotiabank
65 USD
Upside 65%
6 months ago
Apr 17, 2024
Scotiabank Upgrades Legend Biotech Corp. (LEGN) to Sector Outperform
StreetInsider
Rick Bienkowski
Cantor Fitzgerald
82 USD
Upside 108%
7 months ago
Apr 3, 2024
Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight
StreetInsider
Kostas Biliouris
BMO Capital
90 USD
Upside 129%
8 months ago
Mar 14, 2024
BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
StreetInsider
Show More Price Targets
Show Less Price Targets
Rick Bienkowski
Cantor Fitzgerald
Price Target 83 USD
Upside/Downside 111%
View Source
Gena Wang
Barclays
Price Target 94 USD
Upside/Downside 139%
View Source
Justin Zelin
BTIG
Price Target 91 USD
Upside/Downside 131%
View Source
Gena Wang
Johnson Rice
Price Target 94 USD
Upside/Downside 139%
View Source
Qize Ding
Redburn Partners
Price Target 86 USD
Upside/Downside 119%
View Source
Edward Tenthoff
Piper Sandler
Price Target 90 USD
Upside/Downside 129%
View Source
Asthika Goonewardene
Truist Financial
Price Target 88 USD
Upside/Downside 124%
View Source
James Shin
Deutsche Bank
Price Target 60 USD
Upside/Downside 52%
View Source
Matthew Harrison
Morgan Stanley
Price Target 82 USD
Upside/Downside 108%
View Source
Leonid Timashev
RBC Capital
Price Target 86 USD
Upside/Downside 119%
View Source
George Farmer
Scotiabank
Price Target 65 USD
Upside/Downside 65%
View Source
Rick Bienkowski
Cantor Fitzgerald
Price Target 82 USD
Upside/Downside 108%
View Source
Kostas Biliouris
BMO Capital
Price Target 90 USD
Upside/Downside 129%
View Source
Show More Price Targets
Show Less Price Targets
Legend Biotech Corp Competitors:
Price Targets
PROB
Probi AB
19% Downside
OCC
Orthocell Ltd
16% Downside
ASND
Ascendis Pharma A/S
61% Upside
CPRX
Catalyst Pharmaceuticals Inc
35% Upside
STTK
Shattuck Labs Inc
67% Upside
HALO
Halozyme Therapeutics Inc
7% Upside
RPTX
Repare Therapeutics Inc
329% Upside
ARTV
Artiva Biotherapeutics Inc
85% Upside

Revenue
Forecast

Revenue Estimate
Legend Biotech Corp

For the last 5 years the compound annual growth rate for Legend Biotech Corp's revenue is 42%. The projected CAGR for the next 3 years is 80%.

42%
Past Growth
80%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Legend Biotech Corp

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Legend Biotech Corp

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LEGN's stock price target?
Price Target
84.8 USD

According to Wall Street analysts, the average 1-year price target for LEGN is 84.8 USD with a low forecast of 60.6 USD and a high forecast of 99.75 USD.

What is Legend Biotech Corp's Revenue forecast?
Projected CAGR
80%

For the last 5 years the compound annual growth rate for Legend Biotech Corp's revenue is 42%. The projected CAGR for the next 3 years is 80%.

Back to Top